1. Home
  2. NCRA vs GLMD Comparison

NCRA vs GLMD Comparison

Compare NCRA & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.19

Market Cap

4.2M

ML Signal

HOLD

Logo Galmed Pharmaceuticals Ltd.

GLMD

Galmed Pharmaceuticals Ltd.

HOLD

Current Price

$0.71

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
GLMD
Founded
2002
2000
Country
Taiwan
Israel
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
4.0M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
NCRA
GLMD
Price
$0.19
$0.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.0M
91.3K
Earning Date
04-15-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,627,944.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.41
52 Week High
$2.40
$2.34

Technical Indicators

Market Signals
Indicator
NCRA
GLMD
Relative Strength Index (RSI) 42.35 57.26
Support Level $0.18 $0.53
Resistance Level $0.25 $0.87
Average True Range (ATR) 0.05 0.07
MACD -0.00 0.01
Stochastic Oscillator 3.69 57.47

Price Performance

Historical Comparison
NCRA
GLMD

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.

Share on Social Networks: